Quick Facts

• Supportive therapy for high levels of triglycerides.
• May be administered to address primary hypercholesterolemia.
• Used adjunctively to a restricted-fat diet to manage mixed dyslipidemia.

---

Fenocid is an approved medication utilized to support the management of certain lipid imbalances in adults. It is typically a component of a comprehensive treatment plan that includes dietary modifications and appropriate physical activity.

Primary Uses and Therapeutic Domains

Fenocid is commonly designated for use as an addition to a cholesterol- and fat-restricted diet to help individuals achieve established therapeutic goals for lipid levels. It is indicated for addressing severe hypertriglyceridemia, a condition involving very elevated levels of triglycerides (fats) in the blood. For individuals with very high triglyceride levels, this approach may contribute to reducing the risk of pancreas-related conditions, such as pancreatitis.

The medication may also be administered to manage primary hypercholesterolemia (high cholesterol) or mixed dyslipidemia, which involves both elevated cholesterol and triglycerides. The treatment goal involves supporting the reduction of elevated total cholesterol, low-density lipoprotein (LDL-C) cholesterol, and triglyceride levels, while also contributing to an increase in high-density lipoprotein (HDL-C) cholesterol.

Who can and cannot use Fenocid? (Fenofibrate Eligibility)

The eligibility for Fenocid use is strictly defined by government regulatory documents, focusing primarily on age, organ function, and specific pre-existing conditions.

Population Eligibility Status	Requirements as per Official Labeling
Approved Population	Adults with the designated lipid disorders (e.g., severe hypertriglyceridemia, mixed dyslipidemia).
Use Not Recommended	Children and adolescents (generally under 18 years), as safety and efficacy have not been established.

Absolute Contraindications

Fenocid is formally contraindicated and must not be used in patients with the following conditions:

• Severe Renal Impairment (e.g., eGFR <30 mL/min/1.73 m^2).
• Active Liver Disease, including primary biliary cirrhosis and unexplained persistent liver function abnormalities.
• Pre-existing Gallbladder Disease.
• Nursing Mothers (breastfeeding).
• Known hypersensitivity to the active compound (fenofibrate or fenofibric acid) or related agents like ketoprofen (photoallergy).

Conditional or Restricted Use

Certain groups are eligible only under specific conditions or require caution:

• Mild to Moderate Renal Impairment ( eGFR 30 to <60 mL/min/1.73 m^2): Use is restricted and typically requires a reduced starting dose.
• Geriatric Patients (ge 65 years): Dosage selection must be based on an assessment of the patient's renal function.
• Pregnancy: Use is generally only recommended if the potential benefit definitively justifies the potential risk, as officially assessed.

Fenocid (fenofibrate) can interact with several other medications, which may affect its action or increase the risk of side effects. It is critical to inform your healthcare provider about all prescription drugs, over-the-counter medicines, vitamins, and herbal supplements you are currently taking.

Major and Serious Interactions

Particular caution is required when Fenocid is taken alongside certain drug classes, as this can increase the risk of severe muscle problems (myopathy and rhabdomyolysis) or potentiate anticoagulant effects:

• Statins (HMG-CoA reductase inhibitors): Such as atorvastatin, simvastatin, or rosuvastatin. The combination increases the risk of muscle toxicity. If combined, close medical monitoring is essential.
• Oral Anticoagulants (e.g., Warfarin): Fenocid can enhance the effect of these blood thinners, significantly increasing the risk of bleeding. Dosage adjustments and frequent monitoring of the International Normalized Ratio (INR) are necessary.
• Immunosuppressants (e.g., Cyclosporine, Tacrolimus): Concomitant use may lead to a worsening of kidney function (nephrotoxicity).

---

Other Notable Interactions

• Bile Acid Resins: Medications like cholestyramine or colestipol can bind to Fenocid in the gut and impede its absorption. Fenocid must be administered at least 1 hour before or 4 to 6 hours after a bile acid resin.
• Colchicine: Combining Fenocid with colchicine may also increase the risk of myopathy.

Note: Alcohol consumption should be avoided or significantly limited while taking Fenocid, as it can potentially increase the risk of liver damage and pancreatitis.

The core action of Fenocid is driven by its active metabolite, fenofibric acid, which modulates genetic expression to restructure lipid metabolism. The mechanism is strictly defined by a multi-layered action that accelerates the clearance of circulating fats and repositions key lipoprotein levels.

Targeted Regulation of Lipid Genes via PPARalpha Agonism

The mechanism begins at the nucleus by activating the Peroxisome Proliferator-Activated Receptor alpha ( PPARalpha). This activation is a form of genomic signaling that alters the transcription of specific genes responsible for fatty acid breakdown and lipoprotein synthesis within the liver. This modulation of gene expression shapes the subsequent physiological effect.

Accelerated Catabolism of Triglyceride-Rich Particles

PPARalpha agonism initiates a cascade that results in the increased synthesis and activity of the enzyme Lipoprotein Lipase ( LPL), the key component for dismantling triglyceride-rich VLDL particles. Simultaneously, the drug decreases the production of the LPL inhibitor, Apolipoprotein C-III ( ApoC-III). The combined regulatory changes accelerate the catabolism and removal of plasma triglycerides from the circulation.

Modulation of HDL Component Synthesis

In parallel, the mechanism promotes the synthesis of Apolipoprotein A-I and ApoA-II ( ApoA-I/II), the primary structural elements of High-Density Lipoprotein ( HDL) cholesterol. This action influences the assembly of HDL particles, resulting in an increase in circulating HDL levels and affecting the overall lipoprotein profile.

How to Use Fenocid: Official Administration Guidelines

Fenocid, containing the active ingredient fenofibrate, is designated exclusively for oral administration and is typically taken as a tablet or capsule. The primary administration pattern requires the medicine to be taken once daily. The specific numerical strength and whether the dose must be taken with food are formulation-dependent variables. For instance, some Fenofibrate formulations are intended to be taken with a meal to enhance systemic absorption, while other formulations, such as Fenofibric acid, may be taken without regard to food.

---

Dosing and Monitoring Protocol

Standard adult maintenance dosing often falls within a range of 145 mg to 160 mg for fenofibrate or 105 mg for fenofibric acid. These are generally the maximum recommended daily doses. The dose must be selected and adjusted based on the patient's individual lipid response, which is assessed through repeat lipid determinations at intervals of 4 to 8 weeks following the start or change of therapy.

---

Administration Requirements and Patient Populations

Procedural Instruction	Requirement
Swallowing	The tablets or capsules must be swallowed whole and should not be crushed, broken, or chewed.
Concurrent Medications	Fenocid must be administered at least 1 hour before or 4 to 6 hours after bile acid binding resins (e.g., cholestyramine) to prevent impaired absorption.
Renal Impairment	A reduced initial dose (e.g., 35 mg or 48 mg) is required for patients with mild to moderate renal impairment, and use is generally avoided in severe impairment.

The overall treatment protocol requires that the medicine be discontinued if an adequate therapeutic goal is not reached after a period of two months at the maximum recommended dose. If a daily dose is missed, patients are instructed not to take an extra dose, but to resume the schedule with the next planned administration.

Research Evidence: Overview of Clinical Studies

---

Evidence for Use in Modifying Blood Lipid Levels

Research has been conducted to examine Fenocid's profile in adult patients presenting with high cholesterol and mixed dyslipidemia. The evidence relies on large-scale, long-term Randomized Controlled Trials (RCTs) and systematic reviews that combined data from multiple studies. These trials primarily monitored changes in blood biomarkers, including Triglycerides, HDL-C (good cholesterol), and LDL-C (bad cholesterol). Researchers also extensively evaluated the occurrence of major cardiovascular events.

Studies consistently reported measurements of change in triglycerides and HDL-C in the populations studied. However, when assessing the primary outcome of reducing major cardiovascular events across the entire population of some large, long-term trials, the overall findings were mixed compared to the control groups. Further research has explored data patterns in specific groups, and in some subgroups defined by particularly high triglycerides and low HDL-C, the data show patterns related to fewer cardiovascular events being reported.

Evidence for Use in Severe Hypertriglyceridemia

Fenocid was studied for use in adults with very elevated levels of triglycerides (severe hypertriglyceridemia). The existing research includes short-term and intermediate-term RCTs that focused mainly on the rapid modification of blood fats. The primary focus of these trials was observed in measurements of changes in triglyceride levels over short defined time intervals. This research has explored the relationship between measured biomarker changes and the clinical outcome of pancreatitis. Dedicated, long-term clinical trials specifically focused on reducing the risk of pancreatitis are not fully established.

---

Evidence for Use in Managing Diabetic Retinopathy

The research for Fenocid's use in relation to eye health in adults with Type 2 Diabetes is underpinned by large, long-term, prospective RCTs. These studies were evaluated in populations of diabetic adults, some of whom already had signs of diabetic retinopathy. Research highlights changes measured during the study period related to the progression of diabetic retinopathy severity in participants who already had the condition at the start of the trial. The studies also reported that the number of participants requiring treatment was different between the groups observed.

Evidence Gaps and Areas of Uncertainty

Scientific reviews highlight areas of uncertainty where more research is needed or where results are not fully consistent. The primary research limitation is that the findings regarding cardiovascular event reduction were mixed and did not show a clear difference in the overall populations of the largest trials. Additionally, while trials have been conducted over multiple years, the data for very long-term outcomes beyond the duration of the trials remain insufficient.

Common questions about Fenocid (FAQ)

---

Q: What should I do if I forget a dose of Fenocid?

A: If a daily dose is missed, official product information instructs that an extra dose should not be taken to make up for the one that was missed. Patients are advised to simply resume the schedule with the next planned administration.

Q: Can I drink alcohol while taking Fenocid?

A: Regulatory documents recommend that alcohol consumption be avoided or significantly limited while taking Fenocid. The labeling states that consuming alcohol may potentially increase the risk of adverse effects like liver damage and pancreatitis.

Q: Does Fenocid lower LDL cholesterol?

A: Official labeling notes that the medication is indicated for modulating lipid levels. Clinical studies have included monitoring changes in LDL cholesterol (the 'bad' cholesterol) as part of evaluating the overall effects on the lipid profile.

Q: What is the maximum daily dose of Fenocid?

A: According to the official product information, standard adult maintenance dosing for fenofibrate is often in the range of 145 mg to 160 mg. These amounts are referenced in official documentation as generally the maximum recommended daily doses for adult maintenance.

Q: Is Fenocid safe for a 16-year-old with high cholesterol?

A: Official labeling states that the use of Fenocid is generally not recommended for children and adolescents, including those under 18 years of age. This non-recommendation is due to the safety and effectiveness of the medication not being fully established in the pediatric and adolescent populations.

Q: How quickly does Fenocid start working?

A: Official protocols require that the therapeutic response to Fenocid is monitored through repeat lipid determinations after starting or changing therapy. These tests are officially required to be conducted at intervals of four to eight weeks to monitor the patient’s response to therapy.

Q: Can Fenocid be taken in the evening?

A: Fenocid is designated for once-daily oral administration, but the time of day for the dose is not strictly specified. The timing of the dose may depend on the formulation's specific requirement to be taken with or without food, as noted in the product information.

Fenocid Storage and Disposal Instructions

Fenocid (fenofibrate) must be stored under specific conditions to maintain its stability, as required by official regulatory labeling.

Storage Requirements

The medication must be stored at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F). The product must be protected from moisture and kept in the container it was dispensed in, ensuring it remains tightly closed.

Child Safety

Fenocid must be stored out of the reach and sight of children to prevent accidental ingestion.

Disposal Guidance

Official disposal rules require consulting a pharmacist or using an approved drug take-back location to discard any expired or unused medication. This process ensures proper handling and environmental protection; the product is not to be flushed down the toilet.